CSE Requests Clarification and Corporate Update

April 28th, 2020 - Vancouver, BC – Global Care Capital Corp. (CSE:**HLTH,** OTC**: RSCZF,** FRANKFURT**: L6V1**) (the "**Company**" or "**Global Care**") a global investment company which engages in early stage investment opportunities in private and public companies, provides a corporate update to clarify and help investors better understand the ViraxClear transaction (please see the press release from the Company dated April 16th, 2020, outlining the terms of the transaction) and to provide additional corporate updates.

ViraxClear Joint Venture

Shanghai Biotechnology Devices Ltd. ("**SBD**") is a joint venture (the "**Joint Venture**"). SBD is 50% owned by Viral Clear Rapid Test Corp. d/b/a ViraxClear and 50% owned by an arms-length individual based in Hong Kong. ViraxClear is 100% owned by Global Care Capital Inc. Under the terms of the Joint Venture, SBD contracts with Shanghai Liangrun Biomedicine Technology Co., Ltd ("**SLB**"), a manufacturer of COVID-19 Test Kits, to brand, market and distribute said Test Kits to the marketplace under the brand "ViraxClear".

Agreement Between SBD and SLB

SBD currently contracts with SLB pursuant to the terms of a sales agreement in which SBD purchases Antibody COVID-19 Test Kits manufactured by SLB for the purposes of global distribution. Under the terms of this arrangement, SBD provides production orders to SLB from time to time as it identifies sales opportunities and SLB prioritizes production from its facilities to support these orders.

Status of FDA Emergency Use Authorization Designation

The Emergency Use Authorization (EUA) authority allows the Food and Drug Administration (FDA) to help strengthen the United State's public health protections against Chemical, Biological, Radiological and Nuclear (CBRN) threats by facilitating the availability and use of Medical Counter Measures (MCMs) needed during public health emergencies.

Under section 564 of the Federal Food, Drug, and Cosmetic Act (FD&C Act), the FDA Commissioner may allow unapproved medical products or unapproved uses of approved medical products to be used in an emergency to diagnose, treat, or prevent serious or life-threatening diseases or conditions caused by CBRN threat agents when there are no adequate, approved, and available alternatives.

https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization

The Company wishes to clarify its statement made in its press release dated April 20th, 2020 that ViraxClear had obtained an EUA by the FDA for the COVID-19 test kits it markets and distributes.

The COVID-19 Test Kits manufactured by SLB, that ViraxClear, through the Joint Venture, markets and distributes, are being made available under compliance with Section IV.D. of the FDA's Policy for Diagnostic Tests for COVID-19 during the Public Health Emergency. Updated FDA guidance, issued on March 16th, 2020, allows the distribution of this product for diagnostic use in laboratories or by healthcare workers at the point-of-care. This policy is limited to such testing in laboratories or by healthcare workers at the point-of-care. This policy does not apply to at home testing. The FDA has not reviewed SLB's validation of the test. SBD has applied for FDA approval as a registered foreign exporter on behalf of SLB.

The updated FDA Policy for Diagnostic Tests for COVID-19 can be viewed by clicking the following link:

https://www.fda.gov/media/135659/download

ViraxClear Website

The ViraxClear website, www.viraxclear.com, included an incorrect statement about the COVID-19 Test Kits being FDA approved. All reference to FDA approval was removed from the website as it relates to the Test Kits on March 23rd, 2020.

Letter of Intent for Exclusive Distribution Agreement Between SBD and Shanghai Outdo Biotech

The Company is pleased to announce that on April 28th, 2020, SBD signed a Letter of Intent pursuant to which Shanghai Outdo Biotech Co., Ltd. ("**SOBC**"), a state-owned, Chinese manufacturer that produces COVID-19 Rapid Antibody Test Kits, and SBD, intend to enter a definitive agreement to grant SBD an exclusive right and license to distribute SOBC's COVID-19 Rapid Antibody Test Kits globally, subject to jurisdictional approval requirements being met and conditional on SBD making a minimum US$2,000,000 purchase order. SOBC is representing that the test kits they manufacture have CE marker status, which would allow for sales to the European Market and National Medical Products Administration (NMPA) marker status which would allow for sales to the Chinese market. The Company is awaiting further collateral from SOBC to validate their existing approvals.

Letter of Intent to Form Joint Venture Between SBD and MPI

The Company is pleased to announce that on April 23rd, 2020, SBD signed a Letter of Intent, pursuant to which SBD and MPI Comercializadora ("**MPI**"), a company which specializes in the marketing of electronic products, intend to enter a binding agreement (the "**Agreement**") to form a joint venture entity ("**JVCo**") whereby JVCo will fund, purchase COVID-19 Antibody Test Kits from SBD for distribution in Mexico and elsewhere determined by the parties. Upon closing of the Agreement, SBD and MPI will each contribute US$50,000 to be used for incorporation of JVCo, and to finance the working capital, inventory and operations of JVCo and which shall be paid back to the parties from the initial revenues of JVCo prior to JVCo distributing dividends. It is anticipated that subject to finalizing the Agreement, JVCo will be 50% owned by SBD and 50% owned by MPI. The brand and suppliers of the test kits to be distributed by JVCo are to be determined.

Other Corporate Updates

Pursuant to the press release issued by the Company on March 31st, 2020, under former name Resinco Capital Partners Inc., in which the Company announced the execution of a share purchase agreement (the "**SPA**") for the sale of all of the issued and outstanding common shares of its wholly-owned subsidiary, ReFormation Pharmaceuticals Corp. ("**ReFormation**"), to an arm-length purchaser, 360 Life Sciences Corp. ("**360**") of Delaware, United States, the Company made the decision on April 6th, 2020, to no longer proceed with the sale of ReFormation to 360 and terminate the SPA without financial penalty or further obligation to the Company.

About ViraxClear

ViraxClear focuses on commercializing novel products that address significant healthcare needs with a specific target on the novel coronavirus (COVID-19). The company's main focus is marketing its ViraxClear Rapid IgM-IgG Combined Antibody Test. The ViraxClear Rapid IgM-IgG Combined Antibody Test for COVID-19 is a lateral flow immunoassay used to qualitatively detect both early and late marker IgG/IgM antibodies.

About Global Care

Global Care Capital is a global investment company which specializes in providing early stage financing to private and public companies. The Company engages in new, early stage investment opportunities in previously underdeveloped assets and obtaining positions in early stage investment opportunities that adequately reflect the risk profile.

GLOBAL CARE CAPITAL CORP.:

Company Contact:

Alex Somjen, President & CEO

asomjen@globalcarecapital.com

Tel: 416-319-5744

Neither the CSE nor its regulation services provider accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Information: This news release includes certain statements that may be deemed "forward-looking statements". The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "would", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents which can be found under the Company's profile on www.sedar.com